EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Radium-223 alters the levels of soluble immune regulators in the plasma of patients with metastatic castrate-resistant prostate cancer

Lunj S, Mistry H, Christodoulou T, Smith Tad, Song Y, Nightingale H, Patel K, Cutting P, Kelthy M, Greenhalgh M, Reeves Kj, West C und 4 weitere

Cancer Treatment and Research Communications · 2026 · 49 · 101381

DOI: 10.1016/j.ctarc.2026.101381 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Lunj S und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of Manchester, Division of Cancer Sciences, Oglesby Cancer Research Building, Wilmslow Rd, Manchester, M20 4GJ, UK. Electronic address: sa…. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Cancer Research UK Manchester Centre, Movember Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The approval of Radium 223 (Ra-223) has played an important role in the management of patients with metastatic castrate-resistant prostate cancer (mCRPC) by demonstrating improved symptom control and overall survival. However, not all patients respond, leading to an urgent need to develop combination therapies to improve patient outcome. Clinical studies investigating the efficacy of combining Ra-223 with immune checkpoint inhibitors (ICIs) have demonstrated limited success. A lack of understanding of how Ra-223 monotherapy alters immune regulators may play a role in the failure of these clinical studies. To address this knowledge gap, we collected plasma samples from patients with mCRPC treated with Ra-223 (n = 43) and aimed to first establish whether 61 relevant soluble immune regulators could be measured in patients with mCRPC and whether Ra-223 monotherapy modulates the expression of these regulators. Our study confirmed that soluble immune regulators can be detected in the plasma of patients with mCRPC and that Ra-223 significantly alters some of these regulators during treatment. Importantly, a differential response is observed in patients classified as non-responders and responders to Ra-223. With non-responders demonstrating treatment-induced changes in chemokines, matrix metalloproteinases and immune checkpoint molecules that occurred throughout the schedule. Whereas, in responders Ra-223 mostly induced early changes in cytokines, immune checkpoint and apoptotic cell clearance molecules. Our study provides much needed patient-derived data that can be further interrogated to better optimise Ra-223 and ICI combination treatment in these patients.

Schlagwörter

Stichwörter der Autor:innen

Immune responseMetastatic prostate cancerRadium 223Soluble immune regulators

Autor:innen und Institutionen

  • University of Manchester, Division of Cancer Sciences, Oglesby Cancer Research Building, Wilmslow Rd, Manchester, M20 4GJ, UK. Electronic address: sapna.lunj@manchester.ac.uk.
  • University of Manchester, Division of Cancer Sciences, School of Pharmacy and Pharmaceutical Sciences, UK.
  • Christie Hospital NHS Foundation Trust, Medical Oncology, Wilmslow Road, Manchester M20 4BX, UK.
  • University of Bangor, Nuclear Futures Institute, School of Computer Science and Electronic Engineering, Dean Street, Bangor ,LL57 1UT, UK.
  • Christie Hospital NHS Foundation Trust, Clinical Oncology, Wilmslow Road, Manchester ,M20 4BX, UK.
  • University of Manchester, Division of Cancer Sciences, Oglesby Cancer Research Building, Wilmslow Rd, Manchester, M20 4GJ, UK.

Förderung

  • Cancer Research UK
  • Cancer Research UK Manchester Centre
  • Movember Foundation
  • NIHR Manchester Biomedical Research Centre

Zitieren

APA

S, L., H, M., T, C., Tad, S., Y, S., H, N., K, P., P, C., M, K., M, G., Kj, R., C, W., P, H., J, H., A, C., & Lv, B. (2026). Radium-223 alters the levels of soluble immune regulators in the plasma of patients with metastatic castrate-resistant prostate cancer. Cancer Treatment and Research Communications, 49, 101381. https://doi.org/10.1016/j.ctarc.2026.101381

Vancouver

S L, H M, T C, Tad S, Y S, H N, et al. Radium-223 alters the levels of soluble immune regulators in the plasma of patients with metastatic castrate-resistant prostate cancer. Cancer Treatment and Research Communications. 2026;49:101381. doi:10.1016/j.ctarc.2026.101381

BibTeX
@article{S2026,
  author = {S, Lunj and H, Mistry and T, Christodoulou and Tad, Smith and Y, Song and H, Nightingale and K, Patel and P, Cutting and M, Kelthy and M, Greenhalgh and Kj, Reeves and C, West and P, Hoskin and J, Honeychurch and A, Choudhury and Lv, Biolatti},
  title = {Radium-223 alters the levels of soluble immune regulators in the plasma of patients with metastatic castrate-resistant prostate cancer},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  volume = {49},
  pages = {101381},
  doi = {10.1016/j.ctarc.2026.101381}
}
Kostenlos starten →